

'Polyfax'

attacks the whole range of pyogenic organisms likely to infect the eye.¹

attacks, in particular, the usually resistant *Pseudomonas pyocyanea*.²

does not develop cross-resistance or cross-sensitisation to other antibiotics.¹

is recommended as prophylactic treatment after corneal injury.²

is indicated in treating conjunctivitis, blepharitis and keratitis, and has been used successfully for the supportive treatment of intracorneal abscess and corneal oedema.³

'Polyfax'

is a most effective and useful ophthalmic ointment.¹

'Polyfax'^{brand} Ophthalmic Ointment

contains Polymyxin B and Bacitracin
in a bland, petrolatum base. (Tubes of 4 G.)


References

1. *Brit. J. Ophthalm.* (1955), **39**, 557
2. *Brit. J. Ophthalm.* (1956), **40**, 159
3. *Brit. J. Ophthalm.* (1965), **49**, 98

Full information is available on request



Burroughs Wellcome & Co. London
(The Wellcome Foundation Ltd.)



eliminate the cross infection risk

Opulets sterile, single dose eye and ear preparations

To overcome the risk of contamination in eye and ear infections, Opulets have been developed as sterile, single dose eye and ear drop tubes and ointment capsules. Each is packed in a film sachet and sterilized by gamma radiation, ensuring effective sterilization, with no loss of activity – the strict criteria of efficacy and safety being met in full.

After each application, these single dose units are discarded, eliminating cross infection risks – each treatment administered by either medical staff or the patient is thus under the most sterile conditions possible in practical medicine.

Opulets provide the lowest unit price available compared with all other preparations of a similar nature. Presentations available at present are:

Atropine Eye Ointment

Atropine Sulphate BP 0.5% w/w.

Chloramphenicol Eye and Ear Drops

Chloramphenicol BP 0.5% w/v.

Chloramphenicol Eye and Ear Ointment

Chloramphenicol BP 1.0% w/w

Fluorescein Eye Drops

Fluorescein Sodium BP 1% w/v.

Hydrocortisone/Neomycin Eye and Ear Ointment

Hydrocortisone Acetate BP 1.5% w/w

Neomycin BP 0.5% w/w.

Physostigmine Eye Drops

Physostigmine (Eserine) Sulphate

BPC 0.5% w/v.

Sulphacetamide Eye Drops


Sulphacetamide Sodium BP 10% w/v.

Sulphacetamide Eye Ointment

Sulphacetamide Sodium BP 6% w/w

full descriptive technical literature is available on request
Pharmax Limited Thames Road Crayford Kent





One in the eye
for *Pseudomonas*
(and most other bacterial
pathogens of the eye)

'Neosporin' has been noted as "preferred to other antibiotics because Polymixin-B is specific for *Pseudomonas*." * But the effectiveness of 'Neosporin' does not end there, for it also contains neomycin sulphate and gramicidin – a combination that is bactericidal to virtually all pathogenic organisms found in the eye.

'Neosporin' Eye Drops are bland, sterile, isotonic with tears and non-irritant. Indicated for the treatment of external bacterial eye infections and prophylaxis before and after ophthalmic surgery. Presented in a specially designed 5 ml. pack to minimise the risk of accidental contamination during use.

* *Amer. J. Ophth.*, 59, 24.

Full information is available on request.

Neosporin
Brand
eye drops



Burroughs Wellcome & Co.
(The Wellcome Foundation Ltd.) **London**



ANNALS OF OPHTHALMOLOGY

30 NORTH MICHIGAN AVENUE • CHICAGO, ILLINOIS 60602 • (312) 238-4673

Ophthalmologists and members of allied disciplines are invited to submit manuscripts on theoretical, experimental, or clinical subjects as well as reports of regional or national Society meetings to the newly founded ANNALS OF OPHTHALMOLOGY.

The new Journal has been founded:

To publish the many worthy papers that, because present ophthalmological journals printed in the English language are extremely congested, must of necessity be rejected for lack of space.

To reduce the great time lapse between submission of papers and their publication thus avoiding delay in making valuable new information available to ophthalmologists. It will be the goal of the editors to publish manuscripts within six months of acceptance.

To provide a medium for the open discussion of new and emerging ideas in all phases of ophthalmology including minority and conflicting viewpoints.

To augment the professional literature of general ophthalmology by providing a much needed facility for the rapid dissemination of theoretical, investigative, medical, and surgical ophthalmology.

To provide a media for a multidisciplinary approach to eye problems.

EDITORIAL BOARD

Editorial Consultant: Dr. Morris Fishbein

- Dr. James Allen, Tulane University, New Orleans, Louisiana
 Prof. José Barraquer, Barraquer De America, Bogota, Colombia
 Dr. John Bellows, Northwestern University, Chicago, Illinois
 Prof. G. B. Bietti, De ll'Universita Di Roma, Rome, Italy
 Dr. R. Castroviejo, Mt. Sinai School of Medicine, New York
 Prof. F. Duch, Universitaire Barcelone, Spain
 Prof. J. Francois, Eye Clinic, University of Ghent, Belgium
 Dr. Louis Girard, Baylor University, Houston, Texas
 Prof. F. Hollwich, Westfälischen Wilhelms-Univ., Munster, Germany
 Prof. Tadeusz Krwawicz, Lublin, Poland
 Prof. S. Lerman, McGill University, Montreal, Canada
 Prof. Isaac Michaelson, Hebrew University, Jerusalem, Israel
 Prof. Pierre-Gerard Moreau, University of Dijon, France
 Prof. H. K. Müller, Universitäts-Augenklinik, Bonn, Germany
 Dr. Akira Nakajima, Juntendo University, Tokyo, Japan
 Dr. David Paton, Johns Hopkins University, Baltimore, Md.
 Prof. Magda Radnot, University of Budapest, Hungary
 Dr. Harold Scheie, University of Pennsylvania, Philadelphia
 Dr. Charles Schepens, Harvard University, Boston, Massachusetts
 Dr. Saul Sugar, Wayne University, Detroit, Michigan
 Prof. P. Trevor-Roper, Westminster Hospital, London, England
 Prof. N. Trantas, A L'Université D'Athènes, Greece

Mail manuscripts and inquiries to: Editorial Correspondent

First issue, June, 1969

**Subscription rate: \$15.00 in U.S.
 Canada and Overseas \$20.00 yearly**